DVAX Stock Forecast: High-risk Player Amidst Potential COVID Vaccine

The Tesla stock forecast was written by Hugh Camiener, Analyst at I Know First. Bachelor of Arts candidate at Columbia University.


  • Dynavax is a commercial state biopharmaceutical company which develops and commercializes vaccines..
  • Dynavax has an FDA approval on their Hepatitis B vaccine, and they have partnered with Sinovac in developing a vaccine for COVID. 
  • The pandemic has caused a significant decline in Dynavax’s revenue, with their net product revenue falling 71% in comparison to Q2 last year.
  • Dynavax’s vaccine partnership with Sinovac has shown positive signs in phase 1 and phase 2 of testing, and their vaccine will be entering phase 3 in Brazil.
  • There is a large amount of volatility in the biopharmaceutical industry; amidst Russia’s self-proclaimed vaccine, Dynavax’s stock fell 9.7%.
  • Dynavax stock forecast remains a high-risk, high reward option..

Read The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

DVAX Stock Forecast: Table Is Being Set – Revenue Growth Is On The Way


The article was written by Amber Zhou, a Financial Analyst at I Know First.

DVAX Stock Forecast

“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.

(Source: mmm-online.com)



  • Competitive Edge and Huge Market Potential from Heplisav-B®
  • Market Doubts about Trial Data of Immuno-Oncology Platform
  • Strong Cash Position from Debt Financing
  • Current I Know First Bullish Forecast For DVAX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Dynavax Stock Analysis: FDA Approval On The Horizon For DVAX Could Provide Tremendous Upside

This article was written by Zachary Shipman, a financial Analyst at I Know First

Dynavax Stock Analysis 

"If approved, this vaccine could offer a better way to protect people from a chronic infection that can cause cirrhosis of the liver, cancer or death," said Robert Janssen, MD, chief medical officer and vice president of clinical development for Dynavax.


  • Dynavax- Healthcare Development
  • Feasibility of Heplisav- B
  • There is room to take a risk and extract value
  • Conclusion & I Know First Forecast

premiumRead The Full Premium Article

Subscribe to our exclusive content in the PREMIUM section here